Splice Bio Appoints David Favre, D.V.M., Ph.D., As Chief Development Officer To Accelerate Development of Its Lead Aav Gene Therapy Program
Splice Bio Appoints David Favre, D.V.M., Ph.D., As Chief Development Officer To Accelerate Development of Its Lead Aav Gene Therapy Program
06/20/23, 7:32 AM
Location
barcelonaIndustry
biotechnology
Position
chief development officer
SpliceBio, a genetic medicines company exploiting its proprietary Protein Splicing platform to develop next generation gene therapies, is pleased to announce the appointment of David Favre, D.V.M., Ph.D., as Chief Development Officer .
Company Info
Location
barcelona, catalonia, spain
Additional Info
SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.